Industry Pipeline - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Pipeline
Interphex Showcase 2010.

Pharmaceutical Technology
Volume 34, Issue 4, pp. 128-135

OUTSOURCING & CONSULTING SERVICES



Contract manufacturing
Cangene bioPharma (formerly Chesapeake Biological Laboratories) offers contract manufacturing for the aseptic fill–finish of liquid and lyophilized sterile injectables into vials and syringes. Cangene provides clinical- and commercial-scale manufacturing, and its clients distribute their products worldwide. Cangene's sites have received approvals from US, European, and Japanese regulatory authorities. Cangene bioPharma, Baltimore, MD http://www.cblinc.com/ tel. 800.441.4225



Protein identification
Orbitrap testing is a protein-identification platform with high sensitivity, rapid scan rate, high mass accuracy and resolution power as high as 100,000. The platform combines a linear, ion-trap mass spectrometer and Orbitrap mass analyzer. Lancaster Laboratories performs comprehensive, accurate identification of proteins in complex sample mixtures. Lancaster Laboratories, Lancaster, PA http://www.lancasterlabs.com/ tel. 717.656.2300



Regulatory services
Dow's strategic guidance early in a topical dermatological program helps speed timing and reduce costs. Dow designs specific nonclinical and chemistry, manufacturing, and controls programs to support applications, negotiates with the US Food and Drug Administration, and prepares submissions. The company recently brought five topical products from inception to approval. Dow Pharmaceutical Sciences, Petaluma, CA http://www.dowpharmsci.com/ tel. 877.369.7476


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here